

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Saint Vincent Carmel Hospital

3. License number 13-23543-01

2. 13500 North Meridian Street
Carmel, Indiana 46032-4903

4. Expiration date October 31, 1990

5. Docket or
Reference No. 030-287676. Byproduct, source, and/or
special nuclear material7. Chemical and/or physical
form8. Maximum amount that licensee
may possess at any one time
under this licenseA. Any byproduct material
listed in Groups I
and II of Schedule A,
Section 35.100 of
10 CFR 35A. Any radiopharmaceutical
listed in Groups I
and II of Schedule A,
Section 35.100 of
10 CFR 35A. As necessary for
uses authorized
in Subitem 9.A.B. Any byproduct material
listed in Group III of
Schedule A, Section
35.100 of 10 CFR 35B. Any form listed in
Group III of Schedule A,
Section 35.100 of
10 CFR 35B. 1 curie
of each byproduct
material authorized
in Subitem 6.B.

C. Xenon-133

C. Gas or gas in solution
that is the subject
of an active (i.e., not
withdrawn or terminated)
"New Drug Application"
(NDA) approved by FDA or
an active (i.e., not
withdrawn, terminated
or on "clinical hold")
"Notice of Claimed
Investigational Exemption
for a New Drug" (IND)
that has been accepted
by FDA

C. 200 millicuries

9. Authorized Use

8511180562 851001
REG3 LIC30
13-23543-01 PDRA. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100
of Title 10, Code of Federal Regulations.B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in
Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Blood flow studies. Pulmonary function studies.

M130 B1 OCT 1 - 1990 2

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

13-23543-01

Docket or Reference number

030-28767

CONDITIONS

10. Licensed material shall be used only at licensee's facilities located at 13500 North Meridian Street, Carmel, Indiana.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material shall be used by, or under the supervision of, Edward C. Wheeler, M.D., Daniel R. Elliott, M.D., John W. Courtney, M.D., Miguel Dizon, M.D., Peter D. Arfken, M.D., John A. Morton, M.D. or Rosalind H. Webb, M.D.
13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
 - (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
 - (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
 - (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

14. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
 - A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
 - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
 - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

13-23543-01

Docket or Reference number

030-28767

15. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated June 29, 1985; letter dated September 5, 1985; and Model ALARA Program dated September 5, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date OCT 1 - 1985

Original Signed
By Evelyn R. Matson
Materials Licensing Section, Region III
COPY